title: Immunohistochemistry for Triple-Negative Breast Cancer.
abstract: Triple-negative breast cancers are a heterogeneous group of tumors that are, as yet, not entirely understood. Although triple-negative carcinomas are strictly defined as invasive carcinomas lacking expression of estrogen receptor, progesterone receptor, and HER2, some use the terms triple-negative and basal-like cancer synonymously. It should be noted that these are not entirely equivalent. Nevertheless, it has been shown that a panel of immunohistochemical markers can be used as a surrogate for genomic profiling and thus to identify basal-like breast cancers. We describe the panels of immunohistochemical markers that can be applied and how to interpret these markers herein.
authors.affiliation: Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK.
authors.forename: Kalnisha
authors.initials: K
authors.lastname: Naidoo
authors.affiliation: Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, 3rd Floor, Bermondsey Wing, Great Maze Pond, London, SE1 9RT, UK. sarah.pinder@kcl.ac.uk.
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Pinder
mesh_terms: D000906:Antibodies / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D010232:Paraffin / Q000302:isolation & purification / Q000378:metabolism; D013194:Staining and Labeling; D013223:Statistics as Topic; D064726:Triple Negative Breast Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: D000906:Antibodies; D010232:Paraffin
keywords: Basal-like breast carcinoma; ER; HER2; Immunohistochemistry; Triple-negative breast cancer